Related Experiment Video
Updated: Dec 13, 2025
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Mustafa Çelebier1, İbrahim Celalettin Haznedaroğlu2
1Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
Insights
High mobility group box-1 (HMGB1) is implicated in COVID-19. Herbal formulations targeting HMGB1 may offer potential treatments for SARS-CoV-2 infection, addressing limitations of current antiviral therapies.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- High mobility group box-1 (HMGB1) is a pro-inflammatory cytokine involved in infection, inflammation, and cancer.
- HMGB1's role in severe acute respiratory syndrome (SARS) and its management via herbal medicine has been explored.
- Current antiviral therapies for viral infections, including COVID-19, have shown limitations.
Purpose of the Study:
- To investigate the potential of targeting HMGB1 in the context of SARS-CoV-2.
- To explore the use of herbal products targeting HMGB1 for COVID-19 management.
Main Methods:
- Literature review on HMGB1's role in inflammation and viral infections.
- Analysis of existing research on herbal formulations and their mechanisms.
Main Results:
- HMGB1 is a potential therapeutic target for COVID-19.
- Herbal products with antiviral and antibacterial properties targeting HMGB1 show promise.
Conclusions:
- External or inhaled herbal preparations targeting HMGB1 could be candidates for clinical management of COVID-19.
- Further research is needed to validate the efficacy of these herbal treatments.
Abstract:
Since the high mobility group box-1 (HMGB1) molecule had been recognized as a proinflammatory cytokine, which mediates endotoxin lethality of mice, there have been lots of papers about targeting the HMGB1 within the contexts of infection, inflammation, and cancer. The pathogenic impact of HMGB1 to the severe acute respiratory syndrome (SARS) and disease management with herbal formulations targeting this unique protein have already been proposed. However, the failure of the numerous current anti-viral therapies on the ongoing viral infections casts reappraisal of the possible interrelationships regarding the HMGB1 and SARS-CoV-2. COVID-19 pandemic due to the SARS-CoV-2 virus is a currently ongoing challenging global health crisis. There is still not any proven exact treatment of COVID-19 with high level of evidence. In this paper, we focused on the potential usage of external and/or inhalation preparation of antiviral/antibacterial herbal products capable of targeting HMGB1 for the clinical management candidates of the ongoing COVID-19 infection.
More Related Videos
12:19Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks
Published on: November 10, 2016
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
